GSK Lotronex Risk Management Plan Should Not Be Altered, Cmte. Says

GlaxoSmithKline's risk management program for Lotronex should not be altered until further data is collected, FDA's Drug Safety & Risk Management Advisory Committee recommended May 5

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet